Therapeutic evolution in HR+/HER2- breast cancer: from targeted therapy to endocrine therapy.

Front Pharmacol · 2024 · PMC10847323 · PMID 38327984

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

The SERD drugs of the same class, camizestrant and giredestrant, both showed a trend to outperform the available drugs, so the clinical trials, CHERA-6 and CAMBRIA-1, were expected to achieve better results.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.